The article. . . 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12

Table of Contents
Addendum

References
(Back to Page 1, Page 2)

81. Wang Y, Aisen P, Casadeval A. Cryptococcus neoformans melanin and virulence: mechanism of action. Infect Immun. 1995;63:3131-6.
82. Williamson PR, Wakamatsu K, Ito S. Melanin biosynthesis in Cryptococcus neoformans. J Bacteriol. 1998;180:1570-2.
83. Nosanchuk JD, Casadevall A. Cellular charge of Cryptococcus neoformans: contributions from the capsular polysaccharide, melanin, and monoclonal antibody binding. Infect Immun 1997;65:1836-41.
84. Nyhus KJ, Wilborn AT, Jacobson ES. Ferric iron reduction by Cryptococcus neoformans. Infect Immun. 1997;65:434-8.
85. Huffnagle GB, Chen GH, Curtis JL, et al. Down-regulation of the afferent phase of T cell-mediated pulmonary inflammation and immunity by a high melanin-producing strain of Cryptococcus neoformans. J Immunol. 1995;155:3507-16.
86. Wang Y, Casadevall A. Susceptibility of melanized and nonmelanized Cryptococcus neoformans to the melanin-binding compounds trifluoperazine and chloroquine. Antimicrob Agents Chemother. 1996;40:541-5.
87. Minari A, Hachem R, Raad I. Candida lusitaniae: a cause of breakthrough fungemia in cancer patients. Clin Infect Dis. 2001;32:186-90.
88. Viscoli C, Girmenia C, Marinus A, et al. Candidemia in cancer patients: a prospective, multicenter surveillance study by the Invasive Fungal Infection Group (IFIG) of the European Organization for Research and Treatment of Cancer (EORTC). Clin Infect Dis. 1999;28:1071-9.
89. Vidotto V, Clerico M, Franzin L, et al. Fungal colonization in patients with cancer of the upper respiratory tract. Mycopathologia. 1986;96:97-101.
90. Idigoras P, Perez-Trallero E, Pineiro L, et al. Disseminated infection and colonization by Scedosporium prolificans: a review of 18 cases. 1990-1999. Clin Infect Dis. 2001;32:E158-65.
91. Sebti A, Kiehn TE, Perlin D, et al. Candida dubliniensis at a cancer center. Clin Infect Dis. 2001;32:1034-8.
92. Manfredini L, Garaventa A, Castagnola E, et al. Fungal infections in pediatric oncology. Pediatr Med Chir. 1995;17:435-41.
93. Park KU, Lee HS, Kim CJ, et al. Fungal discitis due to Aspergillus terreus in a patient with acute lymphoblastic leukemia. J Korean Med Sci. 2000;15:704-7.
94. Gunsilius E, Lass-Florl C, Kahler CM, et al. Candida ciferrii, a new fluconazole-resistant yeast causing systemic mycosis in immunocompromised patients. Ann Hematol. 2001;80:178-9.
95. Quatresooz P, Meiers I, Arrese JE, et al. Clinical case of the month. Disseminated fusariosis in an immunocompromised patient. Rev Med Liege. 2000;55:974-6.
96. Okada H, Hanatani S, Kondo M, et al. Successful treatment of disseminated Fusarium infection in an infant with leukemia. Int J Hematol. 2000;72:494-8.
97. Zmierczak H, Goemaere S, Mielants H, et al. Candida glabrata arthritis: Case report and review of the literature of Candida arthritis. Clin Rheumatol. 1999;18:406-9.
98. Rameh A, Oufroukhi K, Youssef MJ, et al. Cryptococcus neoformans arthritis. A case report. Chir Main. 2000;19:269-71.
99. Acree T, Abreo F, Bagby J. Coccidioidomycosis of the knee diagnosed by fine-needle aspiration: A case report. Diagn Cytopathol. 1998;19:110-2.
100. Kac G, Piriou P, Gueho E, et al. Osteoarthritis caused by Neocosmospora vasinfecta. Med Mycol. 1999;37:213-7.
101. Gunsilius E, Lass-Florl C, Mur E, et al. Aspergillus osteoarthritis in acute lymphoblastic leukemia. Ann Hematol. 1999;78:529-30.
102. Trowbridge J, Ludmer, LM, Riddle VD, et al. Candida lambica polyarthritis in a patient with chronic alcoholism. J Rheumatol. 1999;26:1846-8.
103. Noverr MC, Phare SM, Toews GB, et al. Pathogenic yeasts Cryptococcus neoformans and Candida albicans produce immunomodulatory prostaglandins. Infect Immun. 2001;69:2957-63.
104. Denning DW, Follansbee SE, Scolaro M, et al. Pulmonary aspergillosis in the acquired immunodeficiency syndrome. N Engl J Med. 1991;325:354-7.
105. Tokuda T, Ono Y, Nishyiya H, et al. An autopsy case of fungal (Mucor) cerebral aneurysm. Kansenshogaku Zasshi. 1995;69:438-43.
106. Reiss E, Obayashi T, Orle K, et al. Non-culture based diagnostic tests for mycotic infections. Med Mycol. 2000;38 (Suppl 1):147-59.
107. Makimura K, Murayama SY, Yamaguchi H, Detection of a wide range of medically important fungi by the polymerase chain reaction. J Med Microbiol. 1994;40:358-64.
108. Lass-Florl C, Aigner J, Gunsilius E, et al. Screening for Aspergillus spp. using polymerase chain reaction of whole blood samples from patients with haematological malignancies. Br J Haemato.l 2001;113:180-4.
109. Blunden G, Roch OG, Rogers DJ, et al. Mycotoxins in food. Med Lab Sci. 1991;48:271-82.
110. Agata N, Tanaka H, Shigenobu K, Possible action of cyclopiazonic acid on myocardial sarcoplasmic reticulum: inotropic effects on neonatal and adult rat heart. Br J Pharmacol. 1993;108:571-2.
111. Takahashi M, Tanzawa K, Takahashi S, Adenophostins, newly discovered metabolites of Penicillium brevicompactum, act as potent agonists of the inositol 1,4,5-trisphosphate receptor. J Biol Chem. 1994;269:369-72.
112. Fleckenstein A, Frey M, Fleckenstein-Grun G. Consequences of uncontrolled calcium entry and its prevention with calcium antagonists. Eur Heart J. 1983;Suppl H:43-50.
113. Norred WP, Morrissey RE, Riley RT, et al. Distribution, excretion and skeletal muscle effects of the mycotoxin [14C]cyclopiazonic acid in rats. Food Chem Toxicol. 1985;23:1069-76.
114. Hurne AM, Chai CL, Waring P, Inactivation of rabbit muscle creatine kinase by reversible formation of an internal disulfide bond induced by the fungal toxin gliotoxin, J Biol Chem. 2000;275:25202-6.
115. Liu H, Jackman S, Driscoll H, et al. Immunologic effects of gliotoxin in rats: mechanisms for prevention of autoimmune diabetes mellitus. Ann Clin Lab Sci. 2000;30:366-78.
116. Waring P, Sjaarda A, Lin QH, Gliotoxin inactivates alcohol dehydrogenase by either covalent modification or free radical damage mediated by redox cycling, Biochem Pharmacol. 1995;49:1195-201.
117. Eichner RD, Waring P, Geue AM, et al. Gliotoxin causes oxidative damage to plasmid and cellular DNA. J Biol Chem. 1988;263:3772-7.
118. Siesjo BK, Elmer E, Janelidze S, et al. Role and mechanisms of secondary mitochondrial failure. Acta Neurochir Suppl (Wien). 1999;73:7-13.
119. Clemons KV, Grunig G, Sobel RA, et al. Role of IL-10 in invasive aspergillosis: increased resistance of IL-10 gene knockout mice to lethal systemic aspergillosis. Clin Exp Immunol. 2000;122:186-91.
120. Sutton P, Newcombe NR, Waring P, et al. In vivo immunosuppressive activity of gliotoxin, a metabolite produced by human pathogenic fungi. Infect Immun. 1994;62:1192-8.
121. Kremery V Jr., Kunova E, Jesenska Z, et al. Invasive mold infections in cancer patients: 5 years' experience with Aspergillus, Mucor, Fusarium and Acremonium infections. Support Care Cancer. 1996;4:39-45.
122. Personal communication. Albert MacKenzie, MD. Los Angeles, CA.
123. Van Burik JA, Myerson D, Schreckhise RW, et al. Panfungal PCR assay for detection of fungal infection in human blood specimens. J Clin Microbiol. 1998;36:1169-75.
124. Ionescu G, Bradford RW, Merk M. Redox and free radical monitoring in the clinical practice. J Integrat Med. 1999;3:73-5.
125. Cooke S. Is it fibromyalgia? Making progress with this difficult to diagnose disease. Caring Magazine. 1997;13(1).
126. Available at: http://www.coloradohealthsite.org/fibro/fibro_stats.htm (9/06: Not a valid link.)
127. Available at: http://www.ohsuhealth.com/arthritis/stats.asp (9/06: Page no longer available. Arthritis statistics are available at http://www.ohsuhealth.com/htaz/arthritis/statistics.cfm)
128. Available at: http://www.magnadreampad.com/fibromyalgia.htm
129. Cronan TA, Serber ER, Walen HR, et al. The influence of age on fibromyalgia symptoms. J Aging Health. 2002;14:370-84.
130. Russell IJ, Orr MD, Littman B, et al. Elevated cerebrospinal fluid levels of substance P in patients with the fibromyalgia syndrome. Arthritis Rheum. 1994;37:1593-601.
131. Edwards JE. Invasive Candida infections – evolution of a fungal pathogen. N Engl J Med. 1991;324:1026-31.
132. Masuoka J. Hazen KC. Differences in the acid-labile component of Candida albicans mannan from hydrophobic and hydrophilic yeast cells. Glycobiology 1999;9:1281-6.
133. Wosten HA. Hydrophobins: multipurpose proteins. Annu Rev Microbiol. 2001;55:625-46.
134. Glee PM, Sundstrom P, Hazen KC. Expression of surface hydrophobic proteins by Candida albicans in vivo. Infect Immun. 1995;63:1373-9.
135. Agata N, Tanaka H, Shigenobu K. Possible action of cyclopiazonic acid on myocardial sarcoplasmic reticulum: inotropic effects on neonatal and adult rat heart. Br J Pharmacol. 1993;108:571-2.
136. Chen SC, Halliday CL, Meyer W. A review of nucleic acid-based diagnostic tests for systemic mycoses with an emphasis on polymerase chain reaction-based assays. Med Mycol. 2002;40:333-57.
137. Kurihara K, Miura NN, Uchiyama M, et al., Measurement of blood clearance time by Limulus G test of Candida-water soluble polysaccharide fraction, CAWS, in mice. FEMS Immunol Med Microbiol. 2000;29:69-76.
138. Wasylnka JA, Simmer MI, Moore MM. Differences in sialic acid density in pathogenic and non-pathogenic Aspergillus species. Microbiology. 2001;147:869-77.
139. Takahashi Y, Konishi K, Cisar JO, et al., Identification and characterization of HSA, the gene encoding the sialic acid-binding adhesin of streptococcus gordonii DL1. Infect Immun. 2002;70:1209-18.
140. Kitajma Y. Structural and biochemical characteristics of pathogenic fungus: cell walls, lipids and dimorphism, and action modes of antifungal agents. Nippon Ishinkiin Gakkai Zasshi 2000;41:211-7.
141. Riedel W, Neeck G. Nociception, pain, and antinociception: current concepts. Z Rheumatol. 2001;60:404-15.

Back to Page 1